Same-day pegfilgrastim and chemotherapy

Cancer Investigation

Volumn 23, Issue 7, 2005, Pages 573-576

  Lokich, Jake ^a  

^a Cancer Center of Boston   (United States)

Author keywords

Chemotherapy; Non small cell lung cancer; Same day pegfilgrastim

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; GEMCITABINE; IRINOTECAN; NAVELBINE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TAXANE DERIVATIVE;

ARTICLE; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CLINICAL ARTICLE; DRUG HALF LIFE; DRUG SAFETY; HUMAN; LEUKOCYTOSIS; LEUKOPENIA; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRIDGED COMPOUNDS; CAMPTOTHECIN; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; DEOXYCYTIDINE; DRUG ADMINISTRATION SCHEDULE; FILGRASTIM; HUMANS; LUNG NEOPLASMS; NEUTROPENIA; TAXOIDS; VINBLASTINE;

EID: 33344456247     PISSN: 07357907     EISSN: None     Source Type: Journal    
DOI: 10.1080/07357900500276899     Document Type: Article

References (6)

1. Johnston, E.; Crawford, J.; Blackwell, S.; et al. Randomized, dose escalation study of SD/01 compared with daily filgrastim in patients receiving chemotherapy. J. Clin. Oncol. 2000, 18, 2522-2528.
2. Holmes, F.A.; O'Shaughnessy, J.A.; Vukelja, S.; et al. Blinded, randomized multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or III/IV breast cancer. J. Clin. Oncol. 2002, 20, 727-731.
3. Green, M. A single fixed-dose of pegfilgrastim given once per chemotherapy cycle is as effective as daily filgrastim in the management of neutropenia in high-risk breast cancer. Eur. J. Cancer 2001, 37 (suppl 6), 146 (abstract 540).
4. Lokich, J. Single-dose granulocyte colony-stimulating factor concomitant with multifractionated dose chemotherapy: a strategy for maintaining dose intensity. Cancer Investig. 1999, 17 (7), 547-550.
5. Lokich, J. Multifractionated dosing for chemotherapy with flexible cytokine usage: a strategy for optimizing the therapeutic index. Am. J. Clin. Oncol. 2002, 25, 101-102.
6. Molineux, G.; Kinstler, O.; Briddell, B.; et al. A new form of filgrastim with sustained duration in vivo and enhanced ability to mobilize PBPC in both mice and humans. Exp. Hematol. 1999, 27, 1724-1734.